Loading...
XSHE
002793
Market cap770mUSD
Oct 09, Last price  
4.89CNY
1D
3.16%
1Q
6.30%
Jan 2017
-73.57%
IPO
-7.44%
Name

Luoxin Pharmaceuticals Group Stock Co Ltd

Chart & performance

D1W1MN
XSHE:002793 chart
P/E
—
P/S
2.34
EPS
—
Div yield, %
—
Shrs. gr., 5y
-6.05%
Rev. gr., 5y
-18.89%
Revenues
2.27b
-14.12%
423,429,5782,228,257,0002,529,464,0002,766,788,0003,611,380,0004,117,573,000828,044,0366,211,294,7747,588,790,5756,096,228,9656,477,932,5906,477,932,5893,587,547,0403,587,547,0392,363,867,2262,647,365,1052,273,457,651
Net income
-289m
L-70.11%
32,521,069439,874,000428,585,000443,553,000492,929,000379,198,000115,851,719512,315,288633,950,175320,700,653406,096,223406,096,2300-1,224,926,571-661,138,086-965,496,155-288,580,202
CFO
253m
P
46,531,65233,315,00064,752,39341,830,87958,122,83072,742,004102,274,961114,115,186116,330,2610120,632,9550552,791,495-157,846,935253,065,678
Dividend
May 13, 20220.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Luoxin Pharmaceuticals Group Stock Co., Ltd. is a Chinese pharmaceutical enterprise, primarily focused on the research, development, manufacture, and commercialization of pharmaceutical products. Headquartered in Linyi, the company offers an extensive portfolio of active pharmaceutical ingredients (APIs) and intermediates. These key components cater to a wide array of therapeutic areas, including antiviral and anti-infective treatments, respiratory and digestive system disorders, nervous and endocrine system conditions, cardiovascular health, oncology, and anti-allergy medications. Additionally, it supplies APIs and intermediates for antipyretic, analgesic, and anti-inflammatory drugs. Beyond its core pharmaceutical activities, Luoxin Pharmaceuticals also ventures into the provision of medical treatment and broader health services. The company adopted its current name, Luoxin Pharmaceuticals Group Stock Co., Ltd., in April 2020, having previously operated as Zhejiang Doyin Pump Industry Co., Ltd.

Key people

Yongsheng Wu
Finance Director · since 2025
Zhenteng Liu
Chairman of the Board, General Manager · since 2023
Bohong Sun
Deputy General Manager · since 2021
Xiaotong Zhu
Deputy General Manager · since 2021
Fengsheng Han
Secretary of the Board · since 2023
Zhenfei Liu
Director
Shaohong Ma
Staff Elected Director · since 2026
Yunpei Guo
Independent Director · since 2021
Zhi'ang Wu
Independent Director
Xia Xu
Independent Director
Min Zuo
Independent Director · since 2026
IPO date
Apr 15, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT